Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.

Transplantation proceedings - 1 Dec 2012

Xie L, Nester C M, Reed A I, Zhang Y, Smith R J, Thomas C P

Abstract excerpt

Atypical hemolytic uremic syndrome (aHUS) is characterized by thrombocytopenia, microangiopathic hemolytic anemia, and acute kidney injury (AKI) which frequently progresses to end-stage renal disease (ESRD). In 50% of affected patients, mutations in complement regulatory proteins cause inappropriate complement activation with endothelial injury. Complement factor H (CFH) mutations cause 25% of aHUS cases; these...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Kidney Injury
Share to Atypical Hemolytic Uremic Syndrome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Dosage Calculations

Share to Drug Monitoring

Share to Graft Survival

Share to Hemolytic-Uremic Syndrome

Share to Living Donors

Share to Secondary Prevention

Source

Identifiers

PMID: 23195022
DOI: 10.1016/j.transproceed.2012.07.141

Genes

CFH

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.PMID 23195022Read ↗

Kidney Transplant Outcomes in Patients with Atypical Hemolytic Uremic Syndrome.Semantic proximity Read ↗

Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation.Semantic proximity Read ↗

De novo systemic atypical hemolytic uremic syndrome in an ABO-incompatible living kidney transplant recipient with a novel pathogenic CFHR1 gene mutation successfully treated with eculizumab: a case report.Semantic proximity Read ↗

Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.Semantic proximity Read ↗

Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome.Semantic proximity Read ↗

Prophylactic eculizumab for kidney transplantation in a child with atypical hemolytic uremic syndrome due to complement factor H mutation.Semantic proximity Read ↗

Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation.Semantic proximity Read ↗

Successful 7-Year Eculizumab Treatment of Plasmapheresis-Resistant Recurrent Atypical Hemolytic-Uremic Syndrome due to Complement Factor H Hybrid Gene: A Case Report.Semantic proximity Read ↗

Eculizumab in atypical haemolytic-uraemic syndrome allows cessation of plasma exchange and dialysisSemantic proximity Read ↗

Adult Post-Kidney Transplant Familial Atypical Hemolytic Uremic Syndrome Successfully Treated With Eculizumab: A Case Report and Literature Review.Semantic proximity Read ↗

Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence.Semantic proximity Read ↗

Improved Renal Recovery with Eculizumab Therapy among Children with High Prevalence of Mutation-Associated Atypical Hemolytic Uremic Syndrome: A Retrospective Cohort Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.